Physician profile
Joshua K Wright
NPI 1942941687
$504.58
in general payments reported to CMS, 2019-2025
11 companies · $472 in 2025
The $472 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $32.58 · 2025: $472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $505.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $504.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $169.53 | 2025 | Wegovy |
| Astellas Pharma US INC | $58.41 | 2025 | Veozah |
| Pfizer INC. | $48.21 | 2025 | |
| Lilly USA, LLC | $39.67 | 2025 | Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $35.66 | 2025 | |
| Janssen Pharmaceuticals, INC | $32.58 | 2023 | Invega Sustenna |
| Astrazeneca Pharmaceuticals LP | $32.30 | 2025 | Airsupra |
| Glaxosmithkline, LLC. | $25.65 | 2025 | Arexvy, Shingrix |
| Viiv Healthcare Company | $24.54 | 2025 | Apretude |
| Saluda Medical Americas, INC. | $21.78 | 2025 | Evoke |
| Boston Scientific Corporation | $16.25 | 2025 | Ingevity+ |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.